Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer

US7135549B1 · kind B1 · utility

Assignee

• Latency, LLC · US

Inventors

• Pia M. Challita-Eid · Calabasas, US
• Arthur B. Raitano · Los Angeles, US
• Mary Faris · Los Angeles, US
• Rene S. Hubert · Los Angeles, US
• Karen Jane Meyrick Morrison · Santa Monica, US
• Robert Kendall Morrison · Santa Monica, US
• Wangmao Ge · Tampa, US
• Aya Jakobovits · Beverly Hills, US

Key dates

• Filing date: Apr 9, 2002
• Grant date: Nov 14, 2006
• Expiry date: Oct 12, 2022

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10T436/25
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization.